| Schedule of research and development expenses [Table Text Block] |
| |
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
| |
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
| Research and development expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
| SkinJect |
|
|
|
|
|
|
|
|
|
|
|
|
| Clinical, manufacturing and regulatory activities |
|
1,268,747 |
|
|
1,011,362 |
|
|
2,011,288 |
|
|
2,453,931 |
|
| Professional services and intellectual property |
|
96,653 |
|
|
71,561 |
|
|
145,227 |
|
|
116,678 |
|
| Teverelix |
|
|
|
|
|
|
|
|
|
|
|
|
| Clinical, manufacturing and regulatory activities |
|
2,927,793 |
|
|
- |
|
|
3,850,023 |
|
|
- |
|
| Professional services and intellectual property |
|
46,169 |
|
|
- |
|
|
78,341 |
|
|
- |
|
| Salaries and benefits |
|
568,329 |
|
|
356,641 |
|
|
1,527,207 |
|
|
875,169 |
|
| Total research and development expenses |
|
4,907,692 |
|
|
1,439,564 |
|
|
7,612,085 |
|
|
3,445,778 |
|
| Total general and administrative expenses |
|
6,571,097 |
|
|
4,576,524 |
|
|
12,463,781 |
|
|
7,696,584 |
|
| Total operating expenses |
|
11,478,789 |
|
|
6,016,088 |
|
|
20,075,866 |
|
|
11,142,362 |
|
| Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
| Finance income |
|
- |
|
|
40,004 |
|
|
- |
|
|
63,870 |
|
| Interest income (expense) |
|
(205,638 |
) |
|
- |
|
|
(523,789 |
) |
|
- |
|
| Loss on SEPA settlements |
|
- |
|
|
- |
|
|
(127,083 |
) |
|
- |
|
| Change in fair value of debentures |
|
- |
|
|
(200,000 |
) |
|
|
|
|
(200,000 |
) |
| Total other income (expense) |
|
(205,638 |
) |
|
(159,996 |
) |
|
(650,872 |
) |
|
(136,130 |
) |
| Net loss for the period |
|
(11,684,427 |
) |
|
(6,176,084 |
) |
|
(20,726,738 |
) |
|
(11,278,492 |
) |
|